News25/Ratings8
News · 26 weeks70-56%
2026-03-012026-08-23
Mix2890d
- Insider17(61%)
- SEC Filings7(25%)
- Other2(7%)
- Analyst1(4%)
- Earnings1(4%)
Latest news
25 items- INSIDERDirector Hively Brad sold $1,946,310 worth of shares (298,853 units at $6.51), decreasing direct ownership by 42% to 411,976 units (SEC Form 4)4 - Starling Oncology, Inc. (0001799191) (Issuer)
- SECThe Oncology Institute Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits8-K - Starling Oncology, Inc. (0001799191) (Filer)
- INSIDERLarge owner Chernett Jorey bought $78,480 worth of shares (12,000 units at $6.54), increasing direct ownership by 0.11% to 10,660,858 units (SEC Form 4)4 - Starling Oncology, Inc. (0001799191) (Issuer)
- SECSEC Form 10-Q filed by The Oncology Institute Inc.10-Q - Starling Oncology, Inc. (0001799191) (Filer)
- SECThe Oncology Institute Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Starling Oncology, Inc. (0001799191) (Filer)
- SECThe Oncology Institute Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Oncology Institute, Inc. (0001799191) (Filer)
- PRThe Oncology Institute Rebrands as Starling OncologyCERRITOS, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI" or "the Company"), one of the largest value-based oncology groups in the United States, announced today that it has rebranded to "Starling Oncology, Inc.™." The Company's common stock will begin trading under the new ticker symbol "STLN" on Nasdaq, effective August 4, 2026, replacing its previous ticker symbol "TOI." "We've spent the past several years rebuilding this organization, reaching profitability, and scaling a technology-enabled, highly coordinated care model. We have proven that we have a better solution for both payers and the patients who trust us with accessible, outcomes-focused, high-qua
- INSIDERDirector Kaushal Mohit was granted 33,133 shares, increasing direct ownership by 19% to 205,716 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERDirector Mcgeorge Anne was granted 41,165 shares, increasing direct ownership by 14% to 332,535 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERDirector Pacala Mark L was granted 30,120 shares, increasing direct ownership by 12% to 286,881 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERDirector Stolper Mark was granted 31,124 shares, increasing direct ownership by 120% to 56,957 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERDirector Tzoumakas Kimberly Jo was granted 29,116 shares, increasing direct ownership by 169% to 46,301 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERDirector Hively Brad was granted 27,108 shares, increasing direct ownership by 4% to 710,829 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERDirector Johnson Karen Marie was granted 31,124 shares, increasing direct ownership by 11% to 319,410 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- PRThe Oncology Institute Announces Second Quarter 2026 Earnings Release Date and Conference CallCERRITOS, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI) a pioneer in value-based community oncology care, today announced that the company will release its second quarter 2026 financial results on Thursday, August 6, 2026, to be followed by a conference call the same day at 5:00 p.m. (Eastern Time). The conference call can be accessed live over the phone by dialing 1-833-316-1983 or, for international callers, 1-785-838-9310, and referencing Conference ID: TOI. A replay will be available approximately three hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the liv
- INSIDERLarge owner Chernett Jorey bought $94,860 worth of shares (18,000 units at $5.27), increasing direct ownership by 0.17% to 10,648,858 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERChief Medical Officer Podnos Yale exercised 23,452 shares at a strike of $1.90 and sold $150,340 worth of shares (23,452 units at $6.41) (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERLarge owner Chernett Jorey bought $87,750 worth of shares (15,000 units at $5.85), increasing direct ownership by 0.14% to 10,630,858 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERDirector Tzoumakas Kimberly Jo was granted 17,185 shares (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- INSIDERDirector Stolper Mark was granted 25,833 shares (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- SECThe Oncology Institute Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Oncology Institute, Inc. (0001799191) (Filer)
- PRThe Oncology Institute Completes Strategic Refinancing with OrbiMed, Repaying the Outstanding $86 Million Deerfield Convertible Note, Strengthening its Balance Sheet, and Improving LiquidityCERRITOS, Calif., July 07, 2026 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. ("TOI") (NASDAQ:TOI), one of the largest value-based oncology groups in the United States, announced today that it has repaid its $86 Million senior secured convertible note with Deerfield Partners through a debt refinancing that includes new credit facilities from OrbiMed. This transaction is intended to increase liquidity, improve operating flexibility and extend debt maturities. Under the new financing arrangements with OrbiMed, TOI repaid the outstanding balance of its $86 million senior secured convertible note with a new $75 million term loan with OrbiMed maturing in 2031 as well as approximately $11 mi
- ANALYSTLake Street initiated coverage on The Oncology Institute with a new price targetLake Street initiated coverage of The Oncology Institute with a rating of Buy and set a new price target of $10.00
- INSIDERLarge owner Chernett Jorey bought $90,360 worth of shares (18,000 units at $5.02), increasing direct ownership by 0.17% to 10,615,858 units (SEC Form 4)4 - Oncology Institute, Inc. (0001799191) (Issuer)
- SECThe Oncology Institute Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Oncology Institute, Inc. (0001799191) (Filer)
TOI FAQ
7 questionsWhat does The Oncology Institute Inc. do?
The Oncology Institute, Inc. provides cancer awareness, prevention, diagnosis, treatment, and education service. The company offers chemotherapy education, comprehensive lab testing, pain management, financial counseling, end of life counseling, dietary counseling, in-house infusion center, in-house support groups, in-house pharmacy, nutraceuticals, clinical trials, and educational seminars. It also operates the hope, health, and healing center to offer patients alternative and holistic treatments in addition to chemotherapy. The Oncology Institute, Inc. was founded in 2007 and is based in...Where does TOI stock trade?
The Oncology Institute Inc. (TOI) is listed on NASDAQ.What sector and industry is TOI in?
The Oncology Institute Inc. operates in the Health Care sector, Medical/Nursing Services industry.When did The Oncology Institute Inc. go public?
The Oncology Institute Inc. (TOI) completed its IPO in 2020.What are analysts saying about TOI?
The Oncology Institute Inc. has had 8 recent analyst actions on file. The most recent action was from Lake Street: Buy with a $1000.00 price target on 2026-07-06. Recent price targets range from $250.00 to $1000.00.What companies are similar to TOI?
Notable peers in the same industry include BTSG (BrightSpring Health Services Inc.), HIMS (Hims & Hers Health Inc.), CHE (Chemed Corp), LFST (LifeStance Health Group Inc.), AMED (Amedisys Inc). Compare TOI side-by-side with any of them on Quantisnow.How can I track TOI on Quantisnow?
Quantisnow aggregates The Oncology Institute Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow TOI to receive live email and push alerts on every new disclosure.